Unveiling the Culprit: IL17 Signaling in the Pancreatic Epithelium Drives Tumorigenesis.

IF 8.1 1区医学 Q1 IMMUNOLOGY

Cancer immunology research Pub Date : 2024-09-03 DOI:10.1158/2326-6066.CIR-24-0479

Kyoung Eun Lee, Marina Pasca di Magliano

引用次数: 0

Abstract

IL17 signaling promotes pancreatic cancer development, yet the cell compartment responsible for the protumorigenic function of IL17 has not been defined. In this article, Castro-Pando and colleagues demonstrate that IL17/IL17 receptor A signaling in the pancreatic epithelium is critical for pancreatic cancer initiation and for establishing immunosuppression, whereas its signaling in the immune compartment is dispensable. This work provides an important mechanistic insight on the role of IL17 signaling and identifies a potential new immune checkpoint as a target in pancreatic cancer. See related article by Castro-Pando et al., p. 1170.

查看原文本刊更多论文

揭开罪魁祸首：胰腺上皮细胞中的 IL17 信号驱动肿瘤发生

IL17 信号能促进胰腺癌的发展，但负责 IL17 原发肿瘤功能的细胞区系尚未确定。在这篇文章中，Castro-Pando 及其同事证明了胰腺上皮细胞中的 IL17/IL17 受体 A 信号传导对于胰腺癌的发生和免疫抑制的建立至关重要，而其在免疫细胞区的信号传导则是可有可无的。这项研究从机理上揭示了 IL17 信号传导的重要作用，并确定了一个潜在的新免疫检查点作为胰腺癌的靶点。参见 Castro-Pando 等人的相关文章，第 XXX (3) 页。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer immunology research ONCOLOGY-IMMUNOLOGY

CiteScore

15.60

自引率

1.00%

发文量

260

期刊介绍： Cancer Immunology Research publishes exceptional original articles showcasing significant breakthroughs across the spectrum of cancer immunology. From fundamental inquiries into host-tumor interactions to developmental therapeutics, early translational studies, and comprehensive analyses of late-stage clinical trials, the journal provides a comprehensive view of the discipline. In addition to original research, the journal features reviews and opinion pieces of broad significance, fostering cross-disciplinary collaboration within the cancer research community. Serving as a premier resource for immunology knowledge in cancer research, the journal drives deeper insights into the host-tumor relationship, potent cancer treatments, and enhanced clinical outcomes. Key areas of interest include endogenous antitumor immunity, tumor-promoting inflammation, cancer antigens, vaccines, antibodies, cellular therapy, cytokines, immune regulation, immune suppression, immunomodulatory effects of cancer treatment, emerging technologies, and insightful clinical investigations with immunological implications.